Abiopharma

SERINA THERAPEUTICS, INC. (SER) Reports the reporting period Financial Results SERINA THERAPEUTICS, INC. (SER) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 130
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 19968
  • 252 Phase 1b Registrational Clinical Study: Following completion of sentinel dosing and the independent Safety Monitoring Committee’s recommendation to continue dosing, Serina completed enrollment and dosing of all eight patients in Cohort 1 in July
  • The milestone was achieved ahead of the Company’s previously disclosed guidance of the end of the third quarter of
  • The study protocol provides for a blinded review of Cohort 1 safety and tolerability observations by the independent Safety Monitoring Committee to inform the next dose
    • targeting," “expects,” or “estimates”) should be considered to be forward-looking statement, including statements about the potential of Serina’s POZ polymer technology, Serina’s estimates regarding future revenue, expenses, capital requirements and need for additional financing, and Serina’s planned clinical programs, including planned clinical trials. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory holds, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina’s ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025